Vanda Pharmaceuticals | VNDA - Sales Revenues


Vanda Pharmaceuticals reported $198.77M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
J&J USD 24.1B 500M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.29B 110M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 389M 289M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Takeda JPY 1.19T 80B Dec/2025
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 139.07M 1.53M Mar/2026